Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics
NCT: NCT04130958 · COMPLETED
Brief Summary
This neuroimaging study is a clinical trial investigating the effectiveness of intermittent theta-burst transcranial magnetic stimulation (iTBS-TMS) to the inferior parietal lobule (IPL) in reducing suicide risk in patients with major depressive episode (MDE) or borderline personality disorder (BPD).
Frequently Asked Questions
What is Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics?
Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics is a clinical trial registered under NCT04130958. Current status: COMPLETED.
What is the status of NCT04130958?
The current status of NCT04130958 (Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics) is: COMPLETED.
When did Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics start?
Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics started on 2023-11-01.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.